🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We are hiring! Come join us Memorial Sloan Kettering Cancer Center and study these amazing self-assembling structures that organize RAS signaling and DNA repair! #MSKKids

KRAS(G12D) drives lepidic adeno Ca through stem cell reprogramming nature by Dr. Nicholas Juul et al. G12D in AT1 cells turns them back into AT2 stem to generate indolent tumor. Possible relationship to the higher % of nonsmokers in G12D! #LCSM OncoAlert doi.org/10.1038/s41586…

Today, I had the privilege of lecturing 30 high school students from Japan at UCSF. The topic entailed my practices in Japan and the benefits of conducting research in the U.S. Their vibrant energy invigorated me, and I am thankful to GPI US and UCSF for this great opportunity!

With a chemical biology mindset, truly nothing is undruggable. Here, the active state of KRAS via modified Cyclophilin A ligands. Have been looking forward to seeing this in print. Congratulations, RevMed. science.org/doi/10.1126/sc…

This is why testing for co-mutations is so important. Dr PS research shows that having 2+ tumor supressor genes in EGFR NSCLC indicates aggressive disease. This may help determine if additional treatment is warranted. Make sure your doctors are testing for this

Loved this event! It was such a nice experience meeting new people from both industry and academia. I learned so many things today, and I have to start taking notes before I forget! A huge thank you to the organizers for putting together such a valuable event!!

Members of the Bivona lab at #AACR24 last week!

Just out nature The 1st whole-slide digital pathology #AI foundation model pre-trained on large-scale real-world data, from over 1.3 billion images, 30,000 patients nature.com/articles/s4158… Hoifung Poon Hanwen Xu Microsoft University of Washington Naoto Usuyama Microsoft Research

Excited to head to Chicago for #ASCO24! Looking forward to connecting with my collaborators and colleagues from Japan. Ready to share insights and drive innovation in cancer research!

I'm honored to give a lecture at Fukuoka Institute of Technology in Japan on September 20th. I'll be sharing my invaluable experiences in the US under the title "Challenging Cancer Research Globally! My Study Abroad Experience on the Frontlines.”

I'm heading to Boston tomorrow for the 2024 Damon Runyon Fellows Retreat starting on the 15th. Excited to connect with brilliant cancer researchers from across the US and present my research progress! Looking forward to inspiring discussions!

Keynote speaker at #HTTR24 Dr. Trever Bivona Bivona Lab discussing about the mechanisms involved in tolerance and Resistance to Targeted Therapies. Very inspiring talk. IASLC Jennifer C. King, PhD

Such a pleasure to host and attend HTTR24! Drug resistance in cancer is a fundamental problem limiting cures, but I have so much hope after seeing the new advances emerging from colleagues around the world. Thank you to the speakers and attendees for making this meeting a success

I had a wonderful time at #HTTR24 , IASLC ! Yesterday, I had the opportunity to present our recent work on Exarafenib, a novel therapeutic approach that addresses a critical unmet need in BRAF-mutated lung cancer. Thanks to all the researchers who shared their insights!

Team Bivona Lab at Washington DC for #HTTR24 , IASLC ! Hannah bergo

Join the Bivona Lab team at #AACR25 Chicago on April 29th! Tadashi Manabe MD, PhD 2:30-4:00 PM, Minisymposium Room S102 Yu-Ting 2:00-5:00 PM, Poster Section 18 Nilanjana Chatterjee 2:00-5:00 PM, Poster Section 17 Stop by to discuss our latest research findings! UCSF Helen Diller Family Comprehensive Cancer Ctr UC San Francisco

Excited to present my research on Exarafenib at #AACR25 tomorrow. My work demonstrates promising efficacy against all classes of BRAF mutations in NSCLC, especially Class 2/3 that lack treatment options. #CancerResearch #BRAF #LungCancer

Successfully presented my research on Exarafenib at #AACR25 today. Grateful to the session chairs for their valuable feedback and support. Looking forward to the future of BRAF-targeted therapies in cancer! #CancerResearch #LungCancer #BRAF

It was great to connect with my Japanese colleague on the final day of #AACR25 ! Exciting to exchange ideas on our complementary approaches to tackling NSCLC! Toshio Fujino